Ptaquiloside
Based on 1 Customer Validation
Ptaquiloside (Braxin C; Aquilide A) is an illudane-type sesquiterpene glycoside natural toxin derived from ferns, with carcinogenic properties. Ptaquiloside can be converted to Pterosin B (HY-N1570). Ptaquiloside upregulates the expression of metallothioneins Mt1 and Mt2, and depletes intracellular free zinc ions. Ptaquiloside downregulates the expression of CD44 and CD107a in lesion-infiltrating CD8+ T cells, impairs T cell activation and degranulation capacity, and promotes immune evasion. Ptaquiloside can be used in cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 97.65%
- CAS No.: 87625-62-5
- Formule: C20H30O8
- Masse moléculaire:398.45
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[2]|
MT1 |
MT2 |
In Vitro
Ptaquiloside (10-60 μg/mL; 24 h) activates the ATR-Chk1 DNA damage response in AGS cells, increases γH2AX, and maintains high P53 protein levels, with Chk1 phosphorylated at Ser317 at 60 μg/mL[3].
Ptaquiloside (10-60 μg/mL; 2-24 h) transiently increases P53 transcript levels at 2-6 h and decreases P53 mRNA at 24 h in AGS gastric epithelial cells[3].
Ptaquiloside (60 μg/mL; 24 h) downregulates DNA damage response and DNA repair genes in AGS cells, increasing GADD45A, SESN1, XPC, and PCNA, and decreasing DDIT3, MAP2K6, NBN, RAD50, and RAD51L1[3].
Ptaquiloside-derived PTQ dienone reacts with double-stranded DNA (ODN-3/ODN-4) to form O6-PTBdG and N7-PTBdG guanine adducts[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AGS cell
-
Concentration:0, 10, 40, 60 μg/mL
-
Incubation Time:24 and 48 h
-
Result:Reduced cell viability at the lowest PTA concentration of 10 μg/mL.
-
Cell Line:AGS cell
-
Concentration:0, 40, 60 μg/mL
-
Incubation Time:24 and 48 h
-
Result:Induced modest elevation of late‑apoptotic and necrotic cell counts.
-
Cell Line:AGS gastric epithelial cells
-
Concentration:40 μg/mL
-
Incubation Time:24 h
-
Result:Induced nuclear γH2AX foci and 53BP1 nuclear foci.
-
Cell Line:AGS gastric epithelial cells
-
Concentration:0, 10, 40, 60 μg/mL
-
Incubation Time:24 h
-
Result:Induced dose‑dependent γH2AX up‑regulation after 24 h.
Maintained abundant P53 protein under 24 h graded‑dose PTA treatment.
Activated Chk1 Ser317 phosphorylation at 60 μg/mL PTA, leaving total Chk1 unchanged.
Exerted no influence on total Chk2 and phospho‑Chk2 (Thr68).
-
Cell Line:AGS gastric epithelial cells
-
Concentration:10, 40, 60 μg/mL
-
Incubation Time:2, 6, 24 h
-
Result:Elevated P53 transcript abundance following 2 h and 6 h incubation.
Reduced P53 mRNA levels across all tested PTA doses after 24 h exposure.
-
Cell Line:AGS gastric epithelial cells
-
Concentration:60 μg/mL
-
Incubation Time:24 h
-
Result:Deregulated DNA damage-response and DNA repair genes in AGS cells, increasing GADD45A, SESN1, XPC, and PCNA and decreasing DDIT3, MAP2K6, NBN, RAD50, and RAD51L1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:K14-HPV16 transgenic on FVB/n background (hemizygous female; 18-20 weeks old at start)[1]
-
Dosage:0.5 mg per mouse per week
-
Administration:p.o.; weekly; 10 consecutive weeks
-
Result:Showed 66.7 % premature mortality in ptaquiloside‑treated HPV16+/- mice.
Exhibited universal renal perivascular lymphoblastic infiltration with atypical mitotic figures upon ptaquiloside exposure.
Developed universal severe epidermal dysplasia approaching in‑situ carcinoma in treated HPV16+/- mice.
Revealed unaltered chest‑skin CD8+ T‑cell proportions between treated and untreated HPV16+/- mice.
Diminished CD8+CD107a+ T‑cell fractions in ptaquiloside‑treated HPV16+/- mice.
Reduced CD8+CD44+ activated T‑cell abundance in treated HPV16+/- mice, matching WT mouse levels.
-
Animal Model:C57BL/6J (male, 60-day-old)[2]
-
Dosage:5.3 mg/kg (ptaquiloside); 1.3 mg/kg (selenium)
-
Administration:p.o. (gavage); once daily; 14 days
-
Result:Detected 872 dysregulated transcripts (77 up‑, 795 down‑) in ptaquiloside‑treated splenic NK cells.
Recorded 2.9‑fold Mt1 and 3.0‑fold Mt2 transcript elevation, both annotated to cellular ion‑homeostasis term.
Validated Mt2 up‑regulation by real‑time PCR in treated splenic NK cells.
Identified 302 altered transcripts (47 up‑, 255 down‑) for ptaquiloside‑selenium co‑exposure group.
Chemical Information
-
CAS No. 87625-62-5
-
Appearance Solid
-
Masse moléculaire 398.45
-
Formule C20H30O8
-
Color White to off-white
-
SMILES
C[C@]1(C2(C(C)=C[C@]3([C@]1([H])C([C@@H](C3)C)=O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)CC2)O
-
Synonyms
Braxin C; Aquilide A
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
Ethanol : 25 mg/mL (62.74 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (311 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.5097 mL | 12.5486 mL | 25.0973 mL | 62.7431 mL |
| 5 mM | 0.5019 mL | 2.5097 mL | 5.0195 mL | 12.5486 mL | |
| 10 mM | 0.2510 mL | 1.2549 mL | 2.5097 mL | 6.2743 mL | |
| 15 mM | 0.1673 mL | 0.8366 mL | 1.6732 mL | 4.1829 mL | |
| 20 mM | 0.1255 mL | 0.6274 mL | 1.2549 mL | 3.1372 mL | |
| 25 mM | 0.1004 mL | 0.5019 mL | 1.0039 mL | 2.5097 mL | |
| 30 mM | 0.0837 mL | 0.4183 mL | 0.8366 mL | 2.0914 mL | |
| 40 mM | 0.0627 mL | 0.3137 mL | 0.6274 mL | 1.5686 mL | |
| 50 mM | 0.0502 mL | 0.2510 mL | 0.5019 mL | 1.2549 mL | |
| 60 mM | 0.0418 mL | 0.2091 mL | 0.4183 mL | 1.0457 mL |
Ptaquiloside Related Classifications
HY-N7882 Related Classifications
Powered by Bioz